Key facts
- This page summarizes Pascal Deschatelets's Form 4 filing for Apellis Pharmaceuticals, Inc. (APLS).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 17 Jan 2024, 16:47.
Pascal Deschatelets - 16 Jan 2024 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- APLS
- Reported as of
- 16 Jan 2024
- Net transaction value
- +$541,040
- SEC form
- 4
- Accepted by SEC
- 17 Jan 2024, 16:47:27 UTC
- Prior SEC filing
- 15 Nov 2023
- Next SEC filing
- 23 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Watson, attorney-in-fact for Pascal Deschatelets
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Pascal Deschatelets filed Form 4 for Apellis Pharmaceuticals, Inc. (APLS) on 17 Jan 2024.
Change
- Previous filing in this sequence was filed on 15 Nov 2023.
- Current net transaction value: +$541,040.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
APLS
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +6,743
- Change %
- +0.6%
- Price
- $0.000000
- Shares after
- 1,123,550
- Date
- 16 Jan 2024
- Ownership
- Direct
- Footnotes
- F1
APLS
transaction
Common Stock
Sale
- Transaction value
- $109,032
- Shares
- -1,632
- Change %
- -0.15%
- Price
- $66.81
- Shares after
- 1,121,918
- Date
- 16 Jan 2024
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
APLS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $650,072
- Shares
- +9,805
- Change %
- Price
- $66.30
- Shares after
- 9,805
- Date
- 16 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,805
- Exercise price
- $66.30
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
This represents an award of Restricted Stock Units granted 01/16/2024 that vests annually from grant date over a four year period subject to continued service.
Footnote F2
This represents shares sold to cover tax withholding on the Restricted Stock Units released on 01/12/2024.
Footnote F3
This represents a stock option award granted 01/16/2024 that vests over a four year period. 25% vests one year from grant date and the remaining 75% vests monthly thereafter subject to continued service.